IgG antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis
- PMID: 1626995
- PMCID: PMC1793797
- DOI: 10.1136/adc.67.6.737
IgG antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis
Abstract
The relationship between IgG antibodies to Pseudomonas aeruginosa and its isolation from sputum was determined in 100 patients with cystic fibrosis observed at intervals of two months for a median period of one year. Only one patient had a raised antibody titre (greater than 22.9 ELISA units) before isolation of P aeruginosa. Initially 65 patients were antibody negative, of whom 48 were also culture negative. Of 24 patients with positive sputum culture and negative antibodies, seven became antibody positive at a median (range) 15 (6-25) months later. The remaining 17 patients continued antibody negative until the end of the study at a median range 15 (1-123) months after becoming culture positive. This latter group were younger and had more intermittently positive sputum cultures. In general positive IgG antibody titres do not predate isolation of P aeruginosa, but in some patients are present soon after acquisition of infection. A positive titre indicates significant exposure to P aeruginosa and could be used to detect infection in patients unable to produce sputum and possibly indicate the effect of early antipseudomonal treatment.
Similar articles
-
The value of serum IgG titres against Pseudomonas aeruginosa in the management of early pseudomonal infection in cystic fibrosis.Arch Dis Child. 1992 Sep;67(9):1086-8. doi: 10.1136/adc.67.9.1086. Arch Dis Child. 1992. PMID: 1417051 Free PMC article. Clinical Trial.
-
Serum IgG antibodies in patients with cystic fibrosis with early Pseudomonas aeruginosa infection.Arch Dis Child. 1987 Apr;62(4):357-61. doi: 10.1136/adc.62.4.357. Arch Dis Child. 1987. PMID: 3109335 Free PMC article.
-
Distribution of antibodies to selected antigens of Pseudomonas aeruginosa in children and young adults with cystic fibrosis.Pneumonol Alergol Pol. 2014;82(4):336-41. doi: 10.5603/PiAP.2014.0042. Pneumonol Alergol Pol. 2014. PMID: 24964236
-
Microbiological background for anti-Pseudomonas aeruginosa vaccination in cystic fibrosis.Behring Inst Mitt. 1997 Feb;(98):256-61. Behring Inst Mitt. 1997. PMID: 9382748 Review. No abstract available.
-
IgG subclasses and chronic bacterial infection. Subclass antibodies and the clinical course of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.APMIS Suppl. 1996;66:1-41. APMIS Suppl. 1996. PMID: 8972694 Review. No abstract available.
Cited by
-
Sera from adult patients with cystic fibrosis contain antibodies to Pseudomonas aeruginosa type III apparatus.Infect Immun. 2001 Feb;69(2):1185-8. doi: 10.1128/IAI.69.2.1185-1188.2001. Infect Immun. 2001. PMID: 11160019 Free PMC article.
-
Specific decrease of anti-pseudomonal IgA after anti-pseudomonal therapy in cystic fibrosis.Eur J Pediatr. 1995 Feb;154(2):157-60. doi: 10.1007/BF01991922. Eur J Pediatr. 1995. PMID: 7720747 Clinical Trial.
-
Serum IgG titres against Pseudomonas aeruginosa.Arch Dis Child. 1993 Mar;68(3):432. doi: 10.1136/adc.68.3.432-b. Arch Dis Child. 1993. PMID: 8466253 Free PMC article. No abstract available.
-
Effect of respiratory virus infections including rhinovirus on clinical status in cystic fibrosis.Arch Dis Child. 1995 Aug;73(2):117-20. doi: 10.1136/adc.73.2.117. Arch Dis Child. 1995. PMID: 7574853 Free PMC article.
-
Microbiology of cystic fibrosis lung infections: themes and issues.J R Soc Med. 1993;86 Suppl 20(Suppl 20):11-8. J R Soc Med. 1993. PMID: 7684788 Free PMC article. Review. No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical